The AI platform discovers patterns in patient movement that expert clinicians felt were significant but couldn't objectively measure. This process of data-driven confirmation helps build trust and accelerates the adoption of AI tools by providing evidence for long-held clinical instincts, turning a subjective feeling into objective proof.
In rare diseases with small patient pools, recruiting for clinical trials is a major challenge. Effion Health's highly sensitive digital biomarkers can detect therapeutic efficacy with fewer participants, potentially reducing the required number of patients by 30%, which saves significant time and money for pharmaceutical companies.
To overcome the "black box" problem in medical AI, Effion Health provides clinicians with a dashboard that reveals the specific parameters used to calculate its biomarker score. This transparency allows doctors to understand the AI's reasoning, fostering the trust required for confident clinical decision-making.
Traditional clinical assessments, like the six-minute walk test, are easily skewed by external factors such as patient fatigue. Effion Health's digital biomarker system can isolate and measure the underlying pathological movement patterns, providing a more sensitive and precise measurement of disease progression regardless of temporary conditions.
Rather than aiming directly for high-stakes clinical trials, Effion Health's go-to-market strategy begins with post-market, real-world evidence studies. This approach allows them to demonstrate their technology's value in a real-world setting, building a strong case for adoption in earlier, more critical drug development phases.
Effion Health's core technology was initially for an exoskeleton project. The company's pivotal shift to monitoring Duchenne muscular dystrophy occurred when a friend, whose son has the disease, recognized the sensors' gait analysis potential. This highlights how direct market feedback can redefine a company's entire mission.